==== Front Exp Hematol Oncol Exp Hematol Oncol Experimental Hematology & Oncology 2162-3619 BioMed Central London 424 10.1186/s40164-023-00424-z Correspondence Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting Gong Xubo 1 Zhang Yi 2 He Xin 3 Moloudizargari Milad 3 Yu Teng 4 Wang Lin 1 Liu Weiwei 1 Jin Lan 1 Xu Huiying 1 Xu Yang yxu@zju.edu.cn 4 Tao Zhihua zrtzh@zju.edu.cn 1 Qian Wenbin qianwb@zju.edu.cn 4 1 grid.13402.34 0000 0004 1759 700X Department of Clinical Laboratory, The Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou, 310000 Zheijang P.R. China 2 grid.13402.34 0000 0004 1759 700X Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003 Zheijang P.R. China 3 grid.410425.6 0000 0004 0421 8357 Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope Medical Center, Duarte, CA USA 4 grid.13402.34 0000 0004 1759 700X Department of Hematology, The Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou, 310009 P.R. China 30 6 2023 30 6 2023 2023 12 574 5 2023 23 6 2023 © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. Venetoclax (VEN), the first selective Bcl-2 inhibitor, has shown efficacy and safety both as monotherapy and in combination with other agents in the treatment of newly diagnosed acute myeloid leukemia (AML), while its role in relapsed or refractory (R/R) disease is not well defined. Here, we reviewed the latest advances of VEN-based therapy for R/R AML from the 2022 American Society of Hematology (ASH) Annual Meeting, including some novel and encouraging regimes, such as VCA, VAH, and HAM regimes, etc. Further research is still needed to fully understand the optimal use of these agents in R/R AML treatment. Keywords Venetoclax Acute myeloid leukemia Hypomethylating agents http://dx.doi.org/10.13039/501100001809 National Natural Science Foundation of China 81400107 82100159 Zhejiang Medical and Health Science and Technology Project2022RC154 issue-copyright-statement© YUMED Inc. and BioMed Central Ltd. 2023 ==== Body pmc To the editor, Relapsed or refractory (R/R) acute myeloid leukemia (AML) is associated with a poor prognosis and limited treatment options [1]. The Bcl-2 inhibitor venetoclax (VEN), in combination with hypomethylating agent (HMA) or low-dose cytarabine, was approved by the FDA in 2020 for newly-diagnosed AML in adults 75 years or older, or in patients with comorbidities precluding intensive chemotherapy [2], while its role in R/R disease was not well defined yet. In this study, we provided an overview of the latest updates of VEN-based therapy for R/R AML from the 2022 American Society of Hematology (ASH) meeting. VEN combined with epigenetic drugs for R/R AML The combination of VEN and HMA in R/R AML were investigated by several studies from different countries, which showed overall response rates (ORR) of 44% [3], 52% [4], and 58.8% [5], respectively. Highlighting the regional difference using this combination for R/R AML. 1-year and 2-year overall survival (OS) was 49.6% (95% CI; 39.9-61.8%) and 39.0% (95% CI; 27.2-55.9%) [5], respectively. ASTX727 is an oral agent that combines decitabine with the cytidine deaminase inhibitor cedazuridine. The combination of VEN with ASTX727 [6] achieved an ORR of 53%. With a median follow-up of 7 months, the median OS was not reached. It demonstrates that this combination is feasible with significant efficacy in patients with R/R AML. Chidamide is a subtype-selective benzamide inhibitor of histone deacetylase. In one phase II study [7], the triple combination of VEN, azacitidine (AZA), and chidamide (VCA) achieved an ORR of 75%, and no grade III or IV non-hematologic adverse events (AE) was observed. It shows that VCA is promising with acceptable toxicity for patients with R/R AML. Homoharringtonine (HHT), a natural alkaloid derived from the cephalotaxus, is a well-defined anti-AML agent. The triplet of VEN, HMA, and HHT (VAH) [8] had significantly higher rate of complete remission (CR)/CR with incomplete count recovery (CRi) (63.8% vs. 40.9%, P = 0.003), OS (no reach vs. 16.0 months, P = 0.023) and event-free survival (EFS) (7.1 vs. 2.3 months, P < 0.001) than VEN + HMA group. Subsequently, the data were updated [9] with a median follow-up of 14.7 months, the median OS was 22.1 months, and EFS was 14.3 months. The 1-year OS was 61.5%, and EFS was 51.0%. In this series, the novel VCA and VAH regimes appear to have higher response rate, and the efficacy is worth further exploration. VEN combined with chemotherapy drugs for R/R AML Cladribine is an adenosine deaminase resistant analog of adenosine. After one cycle of VEN, cladribine plus low-dose Ara-C (CAV) [10] for R/R AML, the ORR was 90.5%, the estimated 1-year OS was 91.7%, and the EFS was 74.9%. It suggests that the CAV regimen is a very effective salvage strategy in R/R AML. One phase I/II trial [11] evaluated the combination of VEN with high-dose Ara-C and mitoxantrone (HAM) in patients with R/R AML. The combination was well tolerated and led to CR/CRi of 92%, and 62.5% of evaluable patients were categorized as minimal residual disease (MRD) negative. Desikan et al. [12] updated results of a phase IIb trial, which evaluated the efficacy of the combination of VEN, fludarabine, Ara-C, G-CSF (FLAG), and idarubicin in R/R AML. It had an ORR of 60% with a composite remission rate (CRc) of 53%. Six-month and 12-month OS was 69% and 60%, respectively. 71% of CRc patients attained a MRD negative remission and 68% of responding patients proceeded to transplant. In this series, CAV and HAM regimens seem to have deeper remissions. The efficacy and durability of responses need to be further assessed. VEN combined with antibodies or targeted drugs for R/R AML Pivekimab sunirine (PVEK) can target CD123, which is expressed on the majority of AML blasts and leukemic stem cells. In a phase Ib/II study [13], the combination of VEN, AZA, and PVEK achieved an ORR of 51%, with a composite complete remission (CCR) rate of 31%. Compared to patients with prior VEN exposure, VEN-naïve patients had higher ORR (62% vs. 37%) and CCR (47% vs. 11%). Pegcrisantastase (PegC) is a long-acting crisantastase that exhibits strong anti-leukemia activity through complete consumption of glutamine. An open-label phase Ib clinical trial [14] evaluated the combination of VEN with PegC in R/R AML. The ORR was 64%, with no serious asparaginase-related AE of interest observed. It reveals that VEN-PegC is a well-tolerated regimen. In conclusion, the 2022 ASH annual meeting presented the new development of VEN-based therapy for R/R AML (Tables 1 and 2), including some novel and encouraging regimes, such as VCA, VAH, and HAM, etc. Further research is still needed to fully understand the optimal use of these agents. Table 1 VEN combined with epigenetic drugs for R/R AML Authors (reference) Shahbaz [3] Mohassel [4] Weng [5] Abuasab [6] Zha  [7] Yu  [8] Regimen VEN + HMA VEN + HMA VEN + HMA VEN + ASTX727 VEN + AZA + Chidamide VEN + AZA + HHT Study type Pros Retro Retro N/A Phase II Pros NCT number N/A N/A N/A N/A N/A N/A Study period N/A 2012–2022 N/A N/A N/A N/A Age range (years) 20–67 ≥ 18 N/A 46–92 35–64 N/A Patients number 44 25 136 37 29 231 Response rate ORR 44%, CR/CRi 40% ORR 52%, CR/CRi 36% ORR 58.8%, CR/CRi 44.8% ORR 53%, CR/CRi 46.7% ORR 75%, CR/CRi 56.3% CR/CRi 63.8% Grade ≥ 3 AEs N/A Anemia 80% N/A N/A 0 N/A Follow-up (months) N/A N/A N/A 7 N/A N/A Survival N/A Median OS 9.6 months, median RFS 10.1 months 1- year OS 49.6%, 2-years OS 39.0% Median OS not reached N/A Median OS not reached, median EFS 7.1 months AE adverse events, AML acute myeloid leukemia, AZA azacitidine, CR complete remission, CRi CR with incomplete count recovery, EFS event-free survival, HMA hypomethylating agents, N/A not available, OS overall survival, ORR overall response rate, Pros prospective, R/R relapsed or refractory, Retro retrospective, RFS relapse free survival, VEN venetoclax Table 2 VEN combined with chemotherapy drugs, antibody drugs or targeted drugs for R/R AML Authors (reference) Li  [10] Röllig  [11] Desikan  [12] Daver [13] Bollino [14] Regimen VEN + Cladribine + Ara-C VEN + HAM VEN + FLAG-IDA VEN + AZA + PVEK VEN + PegC Study type N/A Phase-I/II Phase IIb Phase 1b/II Phase Ib NCT number NCT05190549 NCT04330820 N/A NCT04086264 NCT04666649 Study period 2021–2022 2020–2022 N/A N/A N/A Age range (years) 16–68 40–70 18–68 25–82 24–76 Patients number 21 12 33 71 11 Response rate ORR 90.5%, CR/CRi 28.6% CR/CRi 92% ORR 60% ORR 51% ORR 64% Grade ≥ 3 AEs N/A 0 N/A Ferbrile neutropenia 24% 0 Follow-up (months) N/A N/A 15.8 N/A N/A Survival Median OS and EFS not reached, estimated 1-year OS 91.7%, estimated 1-year EFS 74.9% N/A Median OS 27 months, median DOR not reached. Six-month OS 69%, 12-month OS 60% N/A N/A AE adverse events, AML acute myeloid leukemia, CR complete remission, CRi CR with incomplete count recovery, EFS event-free survival, HAM high-dose Ara-C and mitoxantrone, FLAG-IDA fludarabine, Ara-C, G-CSF and idarubicin, N/A not available, OS overall survival, ORR overall response rate, PVEK pivekimab sunirine, PegC pegcrisantastase, R/R relapsed or refractory, VEN venetoclax Abbreviations AE Adverse events AML Acute myeloid leukemia AZA Azacitidine CCR Composite complete remission CR Complete remission CRc Composite remission rate CRi CR with incomplete count recovery EFS Event-free survival FLAG Fludarabine, Ara-C, and G-CSF FDA Food and drug administration HAM High-dose Ara-C and mitoxantrone HHT Homoharringtonine HMA Hypomethylating agents MRD Minimal residual disease ORR Overall response rate OS Overall survival PegC Pegcrisantastase PVEK Pivekimab sunirine R/R Relapsed or refractory VEN Venetoclax Acknowledgements We are thankful to many specialists in the field whose seminal works are not cited due to space constraints. We would like to express my gratitude to all those who helped us during the writing of this review. Author contributions X.G., W.Q., Y.X., and Z.T. were the principal investigators. X.G. and Y.Z drafted the manuscript. T. Y., L. W., and W.L. prepared the tables. All authors participated in the process of drafting and revising the manuscript. All authors read and approved the final manuscript. Funding This work was supported by grants from the Natural Science Foundation of China (grant no. 81400107, 82100159), and Zhejiang Medical and Health Science and Technology Project (2022RC154). Data Availability Not applicable. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare that they have no competing interests. Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Xubo Gong and Yi Zhang contributed equally to this work. ==== Refs References 1. Cao X Dai H Cui Q Li Z Shen W Pan J CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia Exp Hematol Oncol 2022 11 1 67 10.1186/s40164-022-00318-6 36175988 2. Bhansali RS Pratz KW Lai C Recent advances in targeted therapies in acute myeloid leukemia J Hematol Oncol 2023 16 1 29 10.1186/s13045-023-01424-6 36966300 3. Shahbaz N Javed H Response to Hypomethylating Agents Plus Venetoclax in patients with Acute myeloid leukemia and myelodysplastic syndrome: Real World Data from a developing country Blood 2022 140 Suppl 1 13303 4 10.1182/blood-2022-171207 4. Mohassel L Yakubi H Jones K Wang H Shafer D Venetoclax in Combination with Hypomethylating Agents compared to Standard Chemotherapy in Relapsed/Refractory Acute myeloid leukemia Blood 2022 140 Suppl 1 6158 9 10.1182/blood-2022-160260 5. Weng G Zhang Y Yu G Xu N Sun Z Lin D Association of genetic characteristics with response to Venetoclax Plus Hypomethylating Agents in Relapsed and Refractory Acute myeloid leukemia Blood 2022 140 Suppl 1 2025 6 10.1182/blood-2022-158762 6. Abuasab T Garcia-Manero G Short N Alvarado Y Issa GC Islam R Phase 2 study of ASTX727 (cedazuridine/decitabine) plus Venetoclax in patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or previously untreated, Elderly patients with AML Unfit for Chemotherapy Blood 2022 140 Suppl 1 3324 6 10.1182/blood-2022-158566 7. Zha J Zhou H Zhong M Wang Y Du X Gong T Preclinical studies and phase II trial of Venetoclax in Combination with Chidamide and Azacitidine in Relapsed/Refractory Acute myeloid leukemia Blood 2022 140 Suppl 1 3292 3 10.1182/blood-2022-165261 8. Yu G Yin Z Jin H Yu S Li Y Nie D Influence of Molecular Abnormalities on Treatment Response of Venetoclax Plus Azacytidine and Homoharringtonine Versus Venetoclax Plus Hypomethylating Agent in Relapsed/Refractory Acute myeloid leukemia Blood 2022 140 Suppl 1 11796 10.1182/blood-2022-168004 9. Jin H Zhang Y Yu S Du X Xu N Shao R Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: a Multicenter, phase 2 trial J Hematol Oncol 2023 16 1 42 10.1186/s13045-023-01437-1 37120593 10. Li Y Zhou H Wan C Xu M Qian C Zhang T Venetoclax, Cladribine Plus Low-Dose Cytarabine Achieved High Remission in patients with Relapse/Refractory Acute Leukemia: preliminary results of a phase II study Blood 2022 140 Suppl 1 3212 3 10.1182/blood-2022-168054 11. Röllig C Fransecky L Hanoun M Steffen B Kraus S Schliemann C Venetoclax Plus High-Dose Cytarabine and Mitoxantrone as feasible and effective Novel treatment for relapsed AML: results of the Phase-I SAL relax trial Blood 2022 140 Suppl 1 3327 8 10.1182/blood-2022-159897 12. Desikan SP Konopleva M Takahashi K Lachowiez CA Loghavi S Xiao L Updated phase IIb results of Venetoclax with FLAG-IDA in relapsed or refractory Acute Myeloid Leukemia Blood 2022 140 Suppl 1 534 6 10.1182/blood-2022-164922 13. Daver N Montesinos P Aribi A Marconi G Altman JK Wang ES Broad activity for the Pivekimab Sunirine (PVEK, IMGN632), azacitidine, and Venetoclax Triplet in High-Risk patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) Blood 2022 140 Suppl 1 145 9 10.1182/blood-2022-158030 14. Bollino DR Liu Y Bah OM Caprinolo K Zarrabi J Philip S Phase 1 dose escalation trial of pegcrisantaspase in combination with Venetoclax in adults with relapsed or refractory Acute Myeloid Leukemia Blood 2022 140 Suppl 1 9044 5 10.1182/blood-2022-159621